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POLICY
Recommendations for reporting results of diagnostic
genetic testing (biochemical, cytogenetic and
molecular genetic)
Mireille Claustres1, Viktor Kozˇich2, Els Dequeker3, Brain Fowler4, Jayne Y Hehir-Kwa5, Konstantin Miller6,
Cor Oosterwijk7, Borut Peterlin8, Conny van Ravenswaaij-Arts9, Uwe Zimmermann10, Orsetta Zuffardi11,
Ros J Hastings*,12 and David E Barton13, on behalf of the ESHG Quality committee
Genetic test results can have considerable importance for patients, their parents and more remote family members. Clinical
therapy and surveillance, reproductive decisions and genetic diagnostics in family members, including prenatal diagnosis, are
based on these results. The genetic test report should therefore provide a clear, concise, accurate, fully interpretative and
authoritative answer to the clinical question. The need for harmonizing reporting practice of genetic tests has been recognised
by the External Quality Assessment (EQA), providers and laboratories. The ESHG Genetic Services Quality Committee has
produced reporting guidelines for the genetic disciplines (biochemical, cytogenetic and molecular genetic). These guidelines
give assistance on report content, including the interpretation of results. Selected examples of genetic test reports for all three
disciplines are provided in an annexe.
European Journal of Human Genetics (2014) 22, 160–170; doi:10.1038/ejhg.2013.125; published online 14 August 2013
Diagnostic genetic testing is an extremely rapidly expanding area
encompassing a broad range of laboratory investigations to analyse
chromosomes (from classical karyotype to molecular cytogenetics),
nucleic acids (DNA, RNA), proteins and metabolites used to detect
heritable or somatic mutations, genotypes or phenotypes related to
disease and health. Genetic testing requires particular consideration in
that it is usually performed only once in a patient’s lifetime, and the
results may have considerable importance for lifetime decisions not
only for the individuals being tested but also for children and family.
Interpreting and reporting variation in germline chromosomes, DNA
sequences or their products is a heavy clinical responsibility for
prediction of susceptibility to disease, patient diagnosis, prognosis,
counselling, treatment or family planning. Providing a set of
reporting frameworks that can be customised for different testing
contexts but share some common principles could be beneficial to the
practice of a number of laboratories, including non-OECD members
and/or laboratories that do not participate in External Quality
Assessments (EQA), and to laboratories with blurred boundaries
between research and genetic testing services.
Although several guidelines already exist for reporting the results of
genetic testing,1,2,3 these focus on molecular genetic testing and do
not cover the other two branches of laboratory genetics, namely
biochemical genetics and cytogenetics. Based on recent surveys of
EQA results presented by some European EQA providers and the
request from genetic laboratories for comprehensive reporting
guidelines, it was considered that a unifying attempt to harmonise
the reporting practice of genetic tests in Europe and neighbouring
countries would be welcome.
MATERIALS AND METHODS
On behalf of the Genetic Services Quality Committee of the European
Society of Human Genetics (ESHG, https://www.eshg.org/), a workgroup
composed of experts with long-term knowledge and experience in genetic
testing was invited to several meetings, with the objective to answer the
key question: is it feasible to clarify a minimum set of issues and
frameworks in reporting that would fit different testing scenarios encoun-
tered in cytogenetic, molecular and biochemical genetic laboratories?
This workgroup included academic experts in clinical cytogenetics,
molecular genetics, biochemical genetics, clinical genetics, bioinfor-
matics, patient groups, accreditation bodies and EU organisations of
EQA (proficiency testing) for genetic diagnostic laboratories. A pre-
liminary draft including major key issues in reporting was discussed
through meetings, then reviewed and updated by each of the participants,
until reaching a consensus on shape and contents of these guidelines and
recommendations.
Although these guidelines do not specifically address the reporting of results
generated by massively parallel DNA sequencing, the reporting of the
pathogenic variants identified by this method (or their absence) does not
differ from reporting such variants found by conventional DNA sequencing.
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GENERAL COMMENTS
Scope of the document
These recommendations aim to provide guidance for reporting results
of genetic testing by biochemical genetic, cytogenetic and molecular
genetic techniques. They are distinct from (and bring additional
information on reporting to) recently published documents such as
good laboratory practices regulations,4–10 quality assurance
frameworks delivered by EuroGentest (www.eurogentest.org),
evaluation frameworks and assessment of analytic validity developed
by the Agency for Healthcare Research and Quality (AHRQ11), CLIA
(Clinical Laboratory Improvement Amendments) recommendations
for good laboratory practices in molecular genetic testing12 or
guidelines for licensing, certification or accreditation processes and
general guidelines for quality assurance in molecular genetic testing
provided by the Organisation for Economic Cooperation and
Development (OECD).1 Reporting targeted genetic testing for
monogenic disorders and for susceptibility traits with proven
clinical utility, regardless of the extent of testing (that is, single gene
or multiple genes) is within the scope of these recommendations.
Definition
Reports are specific formal medical documents from the laboratory to
the referring physician and/or other health-care professionals regard-
ing the results and interpretation of genetic testing in a patient and/or
members of a family. The main goal of reports is to provide a clear,
concise, accurate, fully interpretative and authoritative answer to a
clinical question.
Minimal set of clinical information accompanying the samples
For the correct interpretation of genetic tests, a minimal set of clinical
information from the referring physician or genetic counsellor must
accompany the sample. The purpose of testing must be clearly
identified (for example, confirmation of diagnosis that was established
by other means, differential diagnosis of several disorders, carrier testing,
presymptomatic testing and prenatal testing). The ethnicity of the
individual tested should be included if relevant for the purpose of
testing; this information may be useful to select the most appropriate
test methods and to calculate residual risks. The referring physician
should provide all clinical, laboratory, imaging, genealogic, genetic or
other data that are relevant to the purpose of testing, and that may
guide the laboratory in selecting the optimal laboratory procedures.
For biochemical genetic testing, the referral should also include
information on the conditions under which the samples were
collected, on fed/fasting status and on the use of medications. For
some clinical situations, it is essential to provide the laboratory with a
family tree constructed by a genetic professional. For index cases,
laboratories are strongly encouraged to request a more detailed
disease-specific clinical form completed by the referring physician
or genetic counsellor. Owing to potential deleterious consequences of
shortcomings in the communication of critical information pertinent
for the interpretation of results and clinical decision-making, some
laboratories provide the ordering clinician with a clinical requisition
form specific for the disease, which must be filled, signed and joined
to the sample. Another benefit is to avoid non-medical office staff
ordering genetic tests.13 If the purpose of testing or relevant clinical
information is not provided, laboratories should request the missing
clinical information required to perform the agreed testing.
Results of how many individuals in one report?
It is recommended that each unrelated patient should be reported in a
separate and unique document, as many reports may ultimately be
filed in individual patient or family files (for reasons of confidenti-
ality). However, in recessive disorders it is appropriate (where legally
permitted) to report the couple’s risk of having affected children
together, which requires that both individuals are clearly identified.
When several family members are analysed simultaneously, policies
vary as to whether they should be reported on the same or on
different reports. This will depend on the disorder and the nature of
the referral reason, as well as on the legislation on genetic testing in
the respective country.
Guidelines for reporting
General guidelines and examples of reports are available in the Annex
to these guidelines and on the ESHG, EuroGentest, CEQA (Cyto-
genetic European Quality Assessment), CF Network and ERNDIM
(European Research Network for evaluation and improvement of
screening, Diagnosis and treatment of Inherited disorders of Meta-
bolism) websites for consultation.
CONTENTS OF THE REPORT
The following elements should be present in every report:
Administrative
Title (for example, ‘Result of molecular genetic analysis of the XX
gene’ or ‘Results of enzyme assay for XX disease(s)’ or ’Results of
constitutional microarray analysis’).
The identity of the laboratory performing the analysis and issuing
the report, with full contact details. If parts of analyses have been
carried out in other laboratories, this fact must be clearly and
unequivocally stated.
Full date of the report.
Page numbers indicating the total number of pages, essential when
multiple pages are used. (for example, 1/1 or page 1 of 2).
Name and full address of the physician referring the patient.
Signature. The report must be electronically or manually signed by
the authorised laboratory specialist who validated the analysis and
interpreted the result; co-validation and co-signature by a second
competent person is recommended (and mandatory in some coun-
tries). The name and function of signatories must be given.
Patient and sample identification
Patient identification:
 Full given name(s) and the surname (must be separate to avoid
uncertainties, especially in sending samples to other countries).
 Unequivocal date of birth.
 Gender.
Fetal samples (CVS, amniocytes and so on) must be clearly
distinguished from those of their mothers.
Note: Where legislation (for example, data protection legislation)
prohibits the transmission of identifiable personal information, a code
may be used instead of the patient’s name.
Ethnic/geographic origin, if relevant.
Date (and time of sample collection, if available; this information is
crucial for biochemical genetic testing).
Date (and time) of sample arrival to the laboratory.
Information on the status of the sample if relevant (for example,
frozen, decomposed, haemolyzed).
Material that has been tested (for example, ‘EDTA blood’, ‘cultured
amniocytes’, ‘DNA extracted fromy’, ‘heparin plasma’, ‘urine’ and
so on). When the sample has been processed in another laboratory
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(for example, DNA has been extracted, plasma has been separated and
frozen, amniocytes have been cultivated and so on) indicate precisely
what was done with the samples and by whom (for example, sample:
‘DNA, extracted by XXXX, from blood’).
Unique sample ID number for each sample tested.
Patient identifiers should be included on each page of a multipage
report.
Restatement of the clinical question
The interpretation of genetic test results depends usually on the
clinical context. Therefore, in the section GENERAL COMMENTS
above, a minimal set of clinical and laboratory data requested from
the referring physician or genetic counsellor has been defined. Based
on this information provided by the attending physician or genetic
counsellor, the reports of genetic testing should explicitly restate the
clinical question being asked. This usually comprises at least the
following three elements:
The disease(s) or marker(s) being requested for analysis (for
example, cystic fibrosis, lysosomal storage disorders, inborn errors of
metabolism, chromosomal abnormalities);
The type of required testing (for example, diagnostic confirmation,
carrier status, prenatal diagnosis);
The referral reason—why the request is being made (for example,
positive family history, multiple congenital abnormalities, fasting
hypoglycaemia and so on).
When the referral is due to abnormal results of previous genetic
testing in either the same laboratory or a different laboratory, this fact
must be clearly indicated in the report, with a reference to the relevant
previous report.
Specification of genetic tests used
Gives useful, brief information on the methods used in the analysis.
Additional information may be in footnotes.
Gives full details of the extent of the tests (for example, which
exons screened for deletions in DMD, which FISH probes used, which
mutations looked for in CF, resolution of cytogenetic analyses and so
on). This information is particularly important when reporting
normal/no abnormality detected results.
Where a commercially available kit is used, this should be clearly
identified in the report, including the reference and version of the kit
(and, where applicable, the list of mutations included in the version
used).
For molecular genetic testing, gives the gene reference sequence that
has been used to identify and describe the variants.
Where appropriate, gives the detection rate (sensitivity) in the
population of origin of the individual tested.
Results
Present the results in a brief and unambiguous form. If several
different tests have been performed, the results should be shown
separately for each of the tests. The terms ‘positive’ and ‘negative’ can
be ambiguous and should not be used.
For molecular genetic testing, reference sequence (including Build
No.) and nomenclature of detected genetic variants should be
meaningful, unambiguous and consistent using the recommended
HGVS nomenclature valid at the time of reporting. As both HGVS
nomenclature and the reference sequences change in time, other
descriptions of the variant that have been widely used in the past may
be given in parentheses, if appropriate.
If more than one possibly pathogenic variant has been detected, a
comment on the phase of variants (which may be unknown) should
be added, taking into account the expected mode of inheritance of the
disorder.
For cytogenetic and microarray testing, the most recent Inter-
national System for Human Cytogenetic Nomenclature (ISCN)
nomenclature should be used.
It may be useful to give a list of genes involved (by HGNC symbol
and/or OMIM number) for abnormal microarray results and for
other tests involving multiple genes.
For biochemical genetic testing using qualitative tests, the report
should clearly distinguish normal results from nonspecific findings
and from clearly abnormal results (including an indication of which
diseases are most likely). For quantitative analyses of single analytes,
both the value and the reference range should be given. For enzyme
assays it is usual to show, in addition, the activities of controls run in
parallel with the patient sample; reports on enzyme activity should
contain the E.C. number of the enzyme. For quantitative profile
analyses, the report should only summarise the major findings
distinguishing normal, nonspecific and disease-specific profiles;
numeric values of the profile analyses should be sent as attachments.
Interpretation of results
General recommendations for the interpretation of genetic laboratory
results are given in this section. The Quality Committee realises that
differences between countries may exist, as to where the boundary of
the responsibilities of laboratory specialist versus the clinician lies. For
example, the use of prediction programs to predict the effect of a
novel missense variant or a variant that may affect splicing is evidently
the expertise and responsibility of the laboratory specialist. The same
holds true for the interpretation of intermediate biochemical results,
although the clinical phenotype may sometimes be decisive for the
interpretation. On the other hand, relating the phenotype to what is
known in literature on the effect of a rare copy number variant will
highly depend on the background of the laboratory specialist
(in some countries, cytogeneticists are clinical geneticists) and
the referring clinician. With the use of new high-resolution-
and high-throughput sequencing techniques, the number of (copy
number) variants of unknown clinical significance will increase, and
the prediction programs and the databases with normal variants have
their limitations. Thus, laboratory and clinical specialists should
discuss and document what the minimal interpretation in the
laboratory report should be. In the opinion of the Quality Commit-
tee, the report should at least contain all relevant information that
enables the clinician to perform the clinical interpretation using
literature resources (for example, which RefSeq genes are located in a
copy number loss, or what the results are of prediction programs on a
missense variant and whether or not it has been reported in databases
like dbSNP). It may be worthwhile to inform the clinician that
genealogical/family studies may be helpful in the interpretation, and
that the interpretation is based on current knowledge and thus may
change in the future due to additional evidence.
Although this is beyond the scope of these recommendations for
reporting results of diagnostic testing, the committee acknowledges
the need for curated locus/disease-specific databases and databases of
copy number variants. Such databases should be supported by an
(international) expert committee (as proposed by Tavtigian et al.14).
The report must provide a full and clear interpretation of results,
depending both on the clinical context and the reason for referral (for
example, diagnostic test, carrier test, prenatal test). Reports on patients
may be read by a variety of professionals involved in their care, many
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of whom will be unable to interpret fully the results of genetic testing.
In order to provide a full interpretation, the results must be viewed in
the context of the relevant clinical and family information available
(for example, relationship between the patient and the index case where
relevant, family pedigree, ethnic background, clinical and laboratory
data provided by the referring physician and others).
If more tests have been carried out using the same sample(s), the
interpretation part of the report should integrate the individual
results and should answer the clinical question in a clear and concise
way. This integration of findings with relevance to the tested
individual is especially important when multiple susceptibility genetic
variants have been analysed.
Answer the question in a concise and clear way, after taking into
account any appropriate additional information supplied. It is
recommended that laboratories highlight this conclusion (bold,
underline, large font, text in a box and so on). In particular,
remember that negative results (‘no mutation detected’) can easily
be misinterpreted by non-specialists as ‘exclusions’. Significance of
results in respect to the referral reason (clinical question) should be
clearly stated and should belong to one the following five categories.
In some cases there may be more than one conclusion:
 Normal finding(s) (physiological finding, normal variation): findings
within the range of physiological variation for the given individual
considering ethnicity, age, sex, maturity and other relevant factors;
for example, nucleic acid sequence corresponding to the reference
sequence or containing genetic variants considered usual variations
at the time of reporting, chromosomal heteromorphisms as defined
in the ISCN, frequently occurring CNVs reported in the database for
genomic variants (DGV), concentrations of analytes in quantitative
biochemical genetic tests within reference ranges, results of qualita-
tive biochemical genetic tests showing a usual result/profile.
If relevant, it may be important to provide an estimate of the
diagnostic sensitivity (that is, the proportion of affected individuals likely
to be detected; or one minus the false-negative rate). It can be useful to
provide a key reference to support sensitivity estimates, when
appropriate, but the report should not become a scientific discussion.
 Non-specific finding(s) without clinical relevance: findings outside
of the physiological variation but not associated with a known
disease; (for example, elevation of multiple serum amino acids in a
patient receiving parenteral nutrition, presence of drugs and their
metabolites in biochemical tests, signs of sample decomposition). Such
findings should only be reported if they may be relevant to the
result (for example, issues of sample quality).
 Incidental finding(s) with possible clinical relevance: findings indicat-
ing a clinically relevant issue, but unrelated to the clinical question
that was asked (for example, signs of sex chromosome abnormality
when analysing an X-linked disorder, evidence of predisposition to an
unrelated condition). The decision on whether to report such findings
will depend on local policy and on how the patient has been
counselled about this possibility. A clear policy on reporting incidental
findings should be in place in all institutions offering genetic testing.
 Finding(s) of uncertain significance: findings outside of the physio-
logical variation but with possible or putative relevance to the
clinical question asked; for example, novel missense variants, novel
putative splicing variants with unproven effect at RNA level,
mosaicism or novel rearrangements in cytogenetic analyses, copy
number variations and intermediate analyte concentration/enzyme
activity, suggesting either heterozygosity or a mild phenotype. It is
important that findings of uncertain significance are included in
reports, as their significance may become clear at a later date.
Attempts should be made to explain significance of the finding using
literature, additional databases, prediction programs and other
means, and to report the likelihood of the finding in respect to
the clinical question asked. In some cases, it may be important to
provide an estimate of diagnostic specificity, which indicates the risk
of a false-positive result (for example, in late-onset diseases or in cases
of reduced penetrance). When practical and appropriate, the advice of
a Clinical Geneticist should be sought.
 Pathognomonic (disease-specific, pathological) finding(s): findings
that are outside of the physiological variation and that are, at the
present state of knowledge, unequivocally associated with a
clinically relevant disease or group of diseases. Pathogenicity of
findings should be clearly supported from data in literature/
databases, segregation analysis, functional tests of genetic variants
and other relevant means.
Description of genotype can include the correct assignment of
phase, which may require the study of familial segregation of alleles.
When appropriate, reports must explicitly mention that ‘both parents
should be tested to confirm their carrier status and to provide formal
confirmation of the diagnosis of their child.’
When appropriate or required by the requesting physician, genetic
carrier risks should be stated. Risk estimates may require the
application of Bayesian calculations.
It should be indicated if further tests could be undertaken to
improve the accuracy or scope of the interpretation. This may include
tests for additional disorders or additional tests to more fully
investigate the disease in question. If the additional tests suggested
are not performed ‘in-house’, alternative specialist laboratories where
the sample may be sent may be proposed.
If any other information could be supplied or obtained by
the referring clinician that might improve the accuracy of your
interpretation, it should be stated in the report (for example,
arranging testing of the index case in a family to confirm a diagnosis
or to determine which mutations are present).
References: It may be useful to quote appropriate references for the
interpretation of results, particularly of rare pathogenic and unclassi-
fied variants, as well as for certain risk calculations.
Requirement for genetic counselling: The report should carry the
reminder to the referring physician that ‘genetic tests should be
accompanied by genetic counselling’ (or similar). In certain cases
(prenatal diagnosis, presymptomatic testing or results with major
implications for other family members), it is appropriate to indicate
that ‘this result and its implications should be transmitted only in a
specialized genetic consultation’ (or similar).
Family follow-up: When a new diagnosis is made (positive result in
a diagnostic confirmation), it is appropriate to state specifically that the
result has ‘potentially important implications for other family members’
or equivalent. Depending on the context, it may be appropriate to
explicitly mention the recommendation to test the partner, the
possibility of cascade screening tests in relatives, the possibility of
prenatal diagnosis or preimplantation genetic diagnosis. Where appro-
priate, the risk for future offspring should be calculated and provided
(using carrier frequencies from an appropriate population).
It should never be stated that prenatal or presymptomatic diagnosis is
‘indicated’ or ‘necessary’. The role of the laboratory does not go beyond
stating that prenatal/presymptomatic diagnosis would be possible.
INTERIM REPORTS
It may in some circumstances be useful to issue a report before all
studies are complete (for example, when indicative preliminary results
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have been obtained, but a long delay is expected before the final
results will be ready). Interim reports should be clearly marked as
such and should be worded to avoid misinterpretation of their status.
Thus, phrases or summary statements appearing to give a definitive
result should not be used. It should be clearly stated which analyses
are still underway.
The definitive report should clearly state which are the new results,
and should include a general conclusion, taking account of all results.
REPORTING MULTIPLE PATIENTS
As a general rule, each unrelated patient should be reported on a
separate and unique document, as the reports will ultimately be filed
in individual patient or family files (as well as for reasons of
confidentiality).
When several family members are analysed simultaneously, policies
vary as to whether they should be reported on the same or on different
reports. This will depend on the disorder, on the nature of the analysis
and also on the legislation (in some countries, familial analysis and
prenatal diagnosis for hereditary disorders can be referred only by
clinical geneticists, and family files are stored only in genetic centres,
and only relevant information is delivered to each individual).
Predictive test results must always be reported as separate,
individual reports.
Linked-marker studies are only useful in the context of alleles
inherited by several family members, which must be included in the
report. It is recommended that the number of individuals
reported should be limited to only those essential for accurate
analysis. An interpretation and final risk should be given for only
one person per report.
For prenatal diagnosis, it is recommended that the report includes
only the result of the fetus. Parental results should be cross-referenced,
but their results reported separately.
In carrier testing for a recessive disorder for a couple, the test results
for one partner must be interpreted in light of the other partner’s
results. Laboratories may issue a single report, or separate reports
with cross references to the partner’s results (as the couple may
separate). It is recognised that, in some jurisdictions, it is not
permissible to mention more than one individual in a clinical report.
Where the result of the parents is needed to interpret the result in
the child, only the array result of the specific CNV(s) in the parents is
given in the child’s report, and not the full array results.
DISCLAIMER
Disclaimers should only be included where they are relevant and
useful; inclusion of multiple disclaimers on every report whether
relevant or not is discouraged.
Where relevant, mention the possibility of errors due to factors
beyond the control of the laboratory (for example, the risk of ‘non-
paternity’ and the need for family relationships as stated on the
referral forms being correct; limited validity of biochemical testing if
pre-analytical conditions were not well controlled).
In indirect (linkage) analyses, it is sometimes advisable to state that
the ‘accuracy of the result depends on the clinical diagnosis and the
assumption that gene X is responsible for the disease’ (or similar).
Laboratories might wish to add a note of caution when reports are
based on DNA samples or reports sent from another laboratory.
It may be advisable to add a standard phrase, indicating that ‘this
report may not be copied or reproduced, except in its totality’.
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